Novavax delivered first quarter results that surpassed Wall Street’s revenue and earnings estimates, leading to a significant positive market reaction. Management attributed the quarter’s performance to strong partner-driven revenue streams, particularly from milestone payments and supply sales tied to agreements with Sanofi and Pfizer. CEO John Jacobs emphasized the shift from direct commercial activity to a strategy anchored by licensing and collaboration, noting, “We now have either licensing partnerships or material transfer agreements with four of the top 10 global pharma companies.” The company also highlighted ongoing cost reductions, with a 23% year-over-year decrease in combined non-GAAP R&D and SG&A expenses, reflecting efforts to build a leaner operating structure.
Is now the time to buy NVAX? Find out in our full research report (it’s free for active Edge members).
Novavax (NVAX) Q1 CY2026 Highlights:
- Revenue: $139.5 million vs analyst estimates of $75.61 million (79.1% year-on-year decline, 84.5% beat)
- Adjusted EPS: -$0.06 vs analyst estimates of -$0.32 (81.3% beat)
- Adjusted EBITDA: -$12.37 million (-8.9% margin, 102% year-on-year decline)
- Operating Margin: -11.1%, down from 77.3% in the same quarter last year
- Market Capitalization: $1.58 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Novavax’s Q1 Earnings Call
- Pete Stavropoulos (Cantor Fitzgerald) asked about the proportion of partner-led vs. Novavax-led experimentation and the mix of novel versus marketed vaccines tested with Matrix-M. CEO John Jacobs explained that most of the 30+ experimental fields are partner-driven and involve both novel and existing assets, while Head of R&D Robert Walker highlighted mucosal immunity as a differentiator for the C. difficile candidate.
- Roger Song (Jefferies) inquired about commercial progress and whether Matrix-M is being evaluated in pneumococcal vaccines, referencing Pfizer’s announcement. Jacobs noted that data has been shared on pneumococcal applications and that partner readiness is key, while CFO James Kelly described the market outlook as “flattish” for the upcoming season.
- Geoffrey Meacham (Citi) questioned the conversion rate from MTA to license and management of overlapping partner fields. Chief Strategy Officer Elaine O’Hara responded that conversion depends on preclinical results, with typical cycles of 4-6 months, and that overlapping, nonexclusive partnerships are viewed as increasing the probability of commercial success.
- Mayank Mamtani (B. Riley Securities) pressed on MTA-to-license cycle times and areas of concentrated partner interest, especially in oncology. O’Hara indicated that timing varies but can be as short as six months, and that oncology—particularly hard-to-treat cancers—is a growing area of strategic focus.
- Thomas Shrader (BTIG) probed the structure of milestone triggers in the Sanofi deal and whether rapid clinical advancement implies mature partner assets. Jacobs clarified that timelines depend on partner readiness, and Kelly explained that Sanofi and Pfizer deal structures are not directly comparable, with milestones tied to both development and sales.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will be watching (1) the pace at which current MTAs transition to full licensing agreements, (2) updates from Sanofi on the commercialization progress of Nuvaxovid and combination vaccines, and (3) continued expansion of Matrix-M applications in both infectious disease and oncology through new and existing partner relationships. Additionally, reductions in operating expenses and new data releases on early-stage pipeline assets could further influence the company’s trajectory.
Novavax currently trades at $9.63, up from $8.10 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
